Items Tagged ‘Lung Cancer’

July 10, 2018

Overall Health, Not Just Age, is an Important Factor in Treatment of Non-Small Cell Lung Cancer

By

Two clinical studies highlight the importance of evaluating overall health instead of age in the management of lung cancer. In fact, younger patients with non-small cell lung cancer (NSCLC) are more likely to receive treatment than older patients, regardless of overall health and prognosis according to the results of a study published in the Journal of […]

View full entry

Tags: Lung Cancer, Lung Cancer - Non-Small Cell, News


June 25, 2018

Precision Cancer Medicine PARP Inhibitor Promising Treatment for Small Cell Lung Cancer

By

The results of a recent study published in The Journal of Clinical Oncology suggest the first new therapeutic option for Small Cell Lung Cancer (SCLC) in many years.  The study evaluated the addition of a novel precision cancer medicine called a PARP inhibitor to standard chemotherapy improved overall response rates and delayed cancer progression in patients […]

View full entry

Tags: Lung Cancer, Lung Cancer - Small Cell, News, PARP Inhibitor Treatment, Precision Cancer Medicine, small cell lung cancer


June 22, 2018

Keytruda Trail Results Suggest Change in Management of Squamous Non-Small Cell Lung Cancer

By

An interim analysis of the phase III KEYNOTE-407 trial evaluated combined chemotherapy and immunotherapy showed a more than four-month longer median overall survival for metastatic squamous non–small-cell lung cancer (NSCLC) patients who received keytruda (pembrolizumab) plus traditional chemotherapy compared with those who received placebo plus chemotherapy. About Lung Cancer Lung cancer remains the leading cause […]

View full entry

Tags: immunotherapy, keytruda, Lung Cancer, News, nsclc, pembrolizumab, Precision Cancer Medicine, squamous non–small-cell lung cancer


June 5, 2018

Xalkori Receives FDA Breakthrough Therapy Designation for Treatment of Lung Cancer with MET Alterations

By

The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for Xalkori (crizotinib) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with MET exon 14 alterations with disease progression on or after platinum-based chemotherapy. The FDA’s Breakthrough Therapy designation is intended to expedite the development and review of a medicine […]

View full entry

Tags: crizotinib, Lung Cancer, Lung Cancer - Non-Small Cell, MET exon 14 alterations, News, non-small cell lung cancer, nsclc, treatment, xalkori


June 4, 2018

Loxo-292 Promising for Lung and Other “RET Fusion” Cancers

By

On Saturday, Loxo Oncology in a presentation at the American Society of Clinical Oncology annual meeting in Chicago unveiled clinical trial data for LOXO-292, a novel precision cancer medicine targeting tumors containing a mutated protein known as RET. About LOXO-202 LOXO-292 is an oral precision cancer medicine that is designed to target cancers with genomic […]

View full entry

Tags: loxo 292, loxo oncology, lung, Lung Cancer, News, pancreatic, Precision Cancer Medicine, RET Fusion, Thyroid Cancer


May 8, 2018

Smoking and Cancer: Understand the Risk and What You Can Do to Control It

By

CancerConnect News: Smoking tobacco cigarettes is responsible for drastically increasing the risk of the developing lung cancer— the number-one cause of cancer-related deaths in the U.S—as well as several other types of cancer (not to mention additional diseases).[1] Tobacco use, primarily from cigarettes, is considered the single most preventable cause of death in this country. […]

View full entry

Tags: Chantix, Lung Cancer, News, quitting smoking, second hand smoke, smoking


April 24, 2018

Alcensa Provides Longer Symptom Improvement than Xalkori in ALK-positive Lung Cancer

By

CancerConnect News: Alecensa (alectinib) provides longer symptom improvement than Xalkori (crizotinib) in ALK-positive non-small-cell lung cancer (NSCLC), according to results presented at the European Lung Cancer Congress in in Geneva, Switzerland.1 About ALK + NSCLC Lung cancer is the leading cause of cancer death in the U.S. and around the world, highlighting the importance of […]

View full entry

Tags: Alcensa, Alecensa, alk-positive, Lung Cancer, Lung Cancer - Non-Small Cell, non-small cell lung cancer, xalkori


April 11, 2018

Overall Health, Not Just Age, is an Important Factor in Treatment of Non-Small Cell Lung Cancer

By

Younger patients with non-small cell lung cancer (NSCLC) are more likely to receive treatment than older patients, regardless of overall health and prognosis, according to the results of a study published in the Journal of Clinical Oncology. Lung cancer remains the leading cause of cancer death in the United States. Non–small cell lung cancer (NSCLC) […]

View full entry

Tags: impact of age on treatment, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer


April 10, 2018

Managing Side Effects From EGFR Inhibitors

By

CancerConnect News: Epidermal Growth Factor Receptor (EGFR) inhibitor drugs are a type of precision cancer medicine commonly used to treat lung, colon, head and neck and other cancers that over express the EGFR.  There are several EGFR inhibitor drugs and these cause similar side effects. The EGFR pathway is a normal biologic pathway found in […]

View full entry

Tags: cetuximab, Colon Cancer, diarrhea, EGFR inhibitors, erbitux, erlotinib, gefitinib, Head and Neck Cancer, iressa, Lung Cancer, News, Panutumamab


February 1, 2018

E-cigarettes May Help Adults Switch From Cigarettes but Encourage Smoking in Teens

By

By AMERICAN HEART ASSOCIATION NEWS CancerConnect News: E-cigarettes can be highly addictive, and kids who use them are more likely to start smoking regular cigarettes, concluded a panel of public health experts. A report released this week by the National Academies of Sciences, Engineering and Medicine is one of the most comprehensive evaluations of existing […]

View full entry

Tags: Lung Cancer, News


January 29, 2018

Roswell Park Research Identifies Link between Smoking, Sex Hormones and Lung Cancer

By

CancerConnect News:  The risk of developing non-small cell lung cancer (NSCLC) is higher for women and smokers according to the results of a recent study published by a team of doctors led by Christine Ambrosone, PhD, Chair of Cancer Prevention and Control from Roswell Park Comprehensive Cancer Center. Researchers have believed that estrogen plays a […]

View full entry

Tags: Gender, hormones, Lung Cancer, News, risk, Women


January 24, 2018

FDA Broadens Gilotrif Indication to Previously Untreated, Metastatic NSCLC with Other Non-Resistant EGFR Mutations

By

CancerConnect News: The Food and Drug Administration (FDA) has granted approval to Gilotrif®  (afatinib) for a broadened indication in first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test. Lung cancer remains the leading cause of cancer death […]

View full entry

Tags: afatinib, EGFR, gilotrif, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, Precision Cancer Medicine


January 17, 2018

Keytruda in Combination with Alimta and Platinum Chemotherapy Improves Survival in Non Small Cell Lung Cancer

By

CancerConnect News: Keytruda (pembrolizumab) is the first PD1 Inhibitor to demonstrate improved overall survival when combined with chemotherapy as primary treatment for metastatic non-squamous non-small cell lung cancer (NSCLC). The KEYNOTE-189 clinical trial evaluated Keytruda in combination with Alimta (pemetrexed) and cisplatin or carboplatin chemotherapy for the first-line treatment of patients with NSCLC. Interim results […]

View full entry

Tags: checkpoint inhibitor, immunotherapy, keytruda, Lung Cancer, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, non-squamous, nsclc, PD1 Inhibitor, pembrolizumab, Precision Cancer Medicine


January 15, 2018

Tagrisso Improves Progression-free Survival in Asian EGFR-mutated Lung Cancer Patients

By

CancerConnect News: Tagrisso (osimertinib) improves progression-free survival compared to standard first line therapy in Asian patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). 1,2 Lung cancer is the number one cause of cancer-related deaths in the United States.  Research identifying specific molecular and genetic components of a patient’s cancer cells has led to […]

View full entry

Tags: EGFR-TKI, first-line treatment, Lung Cancer, News, non-small cell lung cancer, nsclc, osmertinib, tagrisso


January 8, 2018

Ulixertinib A First-in-class ERK Inhibitor Shows Early Efficacy in Patients With Advanced Cancers

By

CancerConnect News: The novel ERK1/2 kinase inhibitor ulixertinib displayed an acceptable safety profile and had clinical activity in patients whose cancers had mutations in the MAPK cell-signaling pathway, according to data from a recent phase 1 clinical trial.  Based on data from this trial, ulixertinib has received the U.S. Food and Drug Administration’s Fast Track […]

View full entry

Tags: Colon Cancer, ERK inhibitor, Lung Cancer, MAPK/ERK, Melanoma, News, Precision Cancer Medicine, targeted therapy, ulixertinib